Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Trial Profile

A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs TIMP-GLIA (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; First in man
  • Sponsors Cour Pharmaceutical Development
  • Most Recent Events

    • 29 Jan 2019 Planned End Date changed from 1 Mar 2019 to 29 May 2019.
    • 29 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 29 May 2019.
    • 09 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top